Alkermes Announces Priority Review By FDA For VIVITROL(R) For Opioid Dependence

Published June 2, 2010

Alkermes Announces Priority Review By FDA For VIVITROL(R) For Opioid Dependence
Alkermes, Inc. (NASDAQ: ALKS) announced that the supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) for opioid dependence has been designated a priority review by the U.S. Food and Drug Administration (FDA). The designation is assigned to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy …